Kanjarla et al., 2023

science
Author

Kanjarla et al.

Year of Publication

2023

Journal

European Journal of Mass Spectrometry

ISSN

1469-0667

Publisher

Sage Publications (London, United Kingdom)

Indexing

Medline, Web of Science, Scopus, Dimensions, Embase

Erratum

Corrigendum (August 1, 2023)

Regenerate response Nadolol is a drug that belongs to Biopharmaceutics Classification System (BCS) class III, with high solubility and low permeability, has low lipid solubility, and a bioavailability of around 35%.1

A corrigendum2 noted that the authors had used ChatGPT without declaration. The acknowledgements were updated, and the editor undertook “preliminary analyses to confirm the authenticity of the datasets.”

Corrigendum

Previously, this page stated that the acknowledgements of the article had been updated to include a declaration of AI use, as was claimed by the corrigendum issued August 1, 2023. However, as of November 15, 2024, the phrase “regenerate response” remains in the text of the article and the acknowledgements contain no such declaration; this is the case in both PDF and HTML. I apologize for neglecting to fact-check the corrigendum. The irony of having to correct myself in this instance is not lost on me.

This article was flagged by Guillaume Cabanac on PubPeer.

References

1Kanjarla N, Pasupuleti B, Boggula N, et al. A HPLC-MS/MS method for the determination of Nadolol in rat plasma: Development, validation, and application to pharmacokinetic study. Eur J Mass Spectrom (Chichester). 2023;29(3):170-180. doi:10.1177/14690667231179569
2Corrigendum. Eur J Mass Spectrom (Chichester). 2023;29(4):272-272. doi:10.1177/14690667231195424